Xias Bio is a technology company.
Xias Bio has raised $5.0M across 1 funding round.
Xias Bio has raised $5.0M in total across 1 funding round.
Xias Bio has raised $5.0M in total across 1 funding round.
Xias Bio's investors include SOSV.
Xias Bio is a biotechnology company developing the world's first molecular platform for multi-functional, animal-free proteins that replace animal-derived ingredients in cosmetics, personal care, and beyond. Its LiteProtein™ platform produces proteins like ElastiLite™ (for wrinkle control) and CollaLite™ (collagen alternative), each performing the work of multiple animal proteins, using a modular fermentation process with a library of 2.6 million proteins.[1][2][4] The company serves cosmetics formulators and suppliers by licensing these sustainable proteins, addressing the $500 billion industry's reliance on livestock byproducts that contribute to emissions, pollution, and deforestation amid consumer demand for cleaner ingredients.[1][2] With 2-10 employees and early commercialization to major leaders, Xias Bio shows strong growth momentum in sustainable biotech.[1][2]
Founded in 2020 in Glasgow, Scotland, Xias Bio was established by Dr. David Harvey, Dr. Faadil Fawzy, and Alister Minty, who bring over 20 years of combined expertise in protein design.[1][4] The idea emerged from the global dependence on animal proteins like collagen (from bovine hides), keratin (chicken feathers), and elastin (meat byproducts) in skincare and haircare, driving ethical, environmental, and sustainability challenges.[1][2] Early traction came quickly through the IndieBio accelerator, development of the LiteProtein™ platform, and licensing deals with cosmetics industry leaders, positioning it as a pioneer in chimeric biology.[1][2][4]
Xias Bio stands out in sustainable biotech through these key strengths:
Xias Bio rides the sustainable biotech and clean beauty wave, capitalizing on two-thirds of consumers demanding animal-free ingredients amid rising pressures from emissions, water pollution, and deforestation in the $500 billion cosmetics sector.[1] Perfect timing aligns with biotech advances in protein engineering and fermentation, enabling cost-competitive alternatives that match or surpass animal proteins.[1][2] Market forces like ethical sourcing mandates and regulatory pushes for sustainability favor its platform, while its influence extends to disrupting animal proteins across the bioeconomy—including AgTech for crop resilience and life sciences—accelerating the shift to circular, low-impact manufacturing.[1][2]
Xias Bio is primed to scale its LiteProtein™ platform beyond cosmetics into AgTech, food, and therapeutics, leveraging early licensing wins and a vast protein library for broader bioeconomy disruption.[1][2] Trends like precision fermentation growth and sustainability regulations will propel expansion, potentially amplifying its role as an innovation partner for formulators worldwide.[2][4][5] As biotech matures, Xias could evolve from niche player to essential supplier, redefining multi-functional proteins and delivering on its promise of superior, ethical alternatives that started with cleaner skincare.[1][2]
Xias Bio has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in April 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2024 | $5.0M Seed | SOSV |